862668--10/12/2010--ESCALON_MEDICAL

related topics

{product, liability, claim}

{control, financial, internal}

{property, intellectual, protect}

{product, market, service}

{interest, director, officer}

{product, candidate, development}

{operation, natural, condition}

{personnel, key, retain}

{acquisition, growth, future}

{regulation, government, change}

{operation, international, foreign}

{stock, price, share}

{provision, law, control}

{system, service, information}

{financial, litigation, operation}

{stock, price, operating}

{loss, insurance, financial}

{cost, operation, labor}

Due to the Company s history of operating losses, the Company s auditors are uncertain that the Company will be able to continue as a going concern. Because the Company s auditors have expressed a going concern qualification, the Company s ability to obtain additional financing could be adversely affected. Any acquisitions, strategic alliances, joint ventures and divestitures that the Company effects could result in financial results that differ from market expectations. The Company continues to have recurring losses from prior acquisitions The Company s results fluctuate from quarter to quarter. ost saving initiatives may not be effective and the Company s ability to develop products could be adversely affected by reduced research and development. Failure of the market to accept the Company s products could adversely impact the Company s business and financial condition. The Company s products are subject to stringent ongoing regulation by the FDA and similar health care regulatory authorities, and if the FDA s approvals or clearances of the Company s products are restricted or revoked, the Company could face delays that would impair the Company s ability to generate funds from operations. The success of products with which the Company s products compete could have an adverse impact on the Company s business. The Company s products employ proprietary technology, and this technology may infringe on the intellectual property rights of third parties. Lack of availability of key system components could result in delays, increased costs or costly redesign of the Company s products. The Company s ability to market or sell the Company s products may be adversely impacted by limitations on reimbursements by government programs, private insurance plans and other third party payors. Future legislation or changes in government programs may adversely impact the market for the Company s products. The Company may become involved in product liability litigation, which may subject the Company to liability and divert management attention. The Company s international operations could be adversely impacted by changes in laws or policies of foreign governmental agencies and social and economic conditions in the countries in which the Company operates. The Company is dependent on its management and key personnel to succeed. The market price of the Company s stock has historically been volatile, and the Company has not paid cash dividends. The impact of terrorism or acts of war could have a material adverse impact on the Company s business. The Company s charter documents and Pennsylvania law may inhibit a takeover. There are inherent uncertainties involved in estimates, judgments and assumptions used in the preparation of financial statements in accordance with United States GAAP. Any changes in estimates, judgments and assumptions used could have a material adverse effect on the Company s business, financial position and operating results.

Full 10-K form ▸

862668--10/12/2010--ESCALON_MEDICAL_CORP